Listen, for the last time: As board members/insiders and as large holders, the Bakers have to file SEC forms every time they buy or sell SGEN shares. They have filed numerous forms reflecting their buys; they have filed no forms reflecting a sale. They have not sold any shares. Is that so hard to understand?
SGEN and Takeda already collaborate worldwide on Adcetris and are in Phase 2 of a trial focused on advanced gastrointestinal malignancies.
One way is to keep an eye on the Twitter feeds of frequent biotech buyers and traders, and to periodically search Twitter for references to Baker brothers, Felix Baker and Julian Baker. That's how I found out fairly quickly some time ago that they opened a position in Mast Therapeutics (MSTX) and later added to it. Based solely on that, I also opened a position in MSTX. Full disclosure - this is essentially a penny stock (now trading at 49 cents a share) and it is an extremely risky investment. But I figure if they're taking a chance on it, I will, too.
The phase 3 trial of brentuximab vedotin included 329 patients, aged 18 and older, who were at high risk of cancer relapse or progression after undergoing stem cell transplant, in which healthy stem cells from the patient are used to replace those lost to cancer or chemotherapy.
The patients were randomly assigned to receive 16 cycles of brentuximab vedotin infusions once every three weeks, or an inactive placebo.
After two years, there was no cancer progression in 65 percent of the patients who received the drug, compared with 45 percent of those in the placebo group, the researchers found. Progression-free survival was 43 months for those who received the drug, compared with 24 months for those in the placebo group.
"Nearly all of these patients who are progression-free at two years are likely to be cured since relapse two years after a transplant is unlikely," Moskowitz said in a journal news release. "No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma," he said.
O'Connor agreed. He said the new findings "represent a significant advance for patients with high-risk Hodgkin lymphoma who relapse or were [unresponsive] following initial therapy."
Common side effects associated with the drug were numbness or pain in the extremities due to nerve damage, and low white blood cell count.
As the researchers explained, brentuximab is an antibody that's attached to a chemotherapy drug that seeks out a protein on Hodgkin lymphoma cells. The drug then "sticks" to the protein and delivers targeted chemotherapy directly into the cancer cells, killing them.
Dr. Jonathan Kolitz is associate chief of hematologic oncology at North Shore-LIJ Cancer Institute in Lake Success, N.Y. He called brentuximab "a welcome addition to strategies aimed at improving outcomes in patients with Hodgkin lymphoma."
Brentuximab has been approved in 50 countries to treat patients with relapsed or treatment-resistant Hodgkin lymphoma, and received U.S Food and Drug Administration approval in 2011.
A four-day-old alias, with an obsession about the Baker brothers and their alleged shorting, which they are not doing. Obviously, another alias of Rickarooski/Maui/Fsout/Smelky, etc. A very ill puppy.
Bull has it right - the Bakers bought another 300,000 or so shares on Monday, March 9, and Tuesday, March 10. One really must wonder what they are up to - why so many huge buys and so consistently. You also really have to wonder why any short is still shorting SGEN. The Bakers are sending every possible signal that there is no future in this for a short - and that the hammer could fall on them at any moment.
Here are a few highlights of CEO Clay Siegall's presentation this morning during the Barclays Healthcare Conference in Miami:
- Takeaway quote: "We think this year can be a fantastic year for Seattle Genetics. We've been building up to this year.."
- The company expects to hear from the FDA in April regarding SGEN's supplemental BLA related to the AETHERA trial, and "we hope to have an additional label for Adcetris before the end of the year."
- He spent a good deal of time on SGN-CD33A and the phase 1 trial in acute myeloid leukemia, a major unmet need for the last 30 years. Clearly, the company is seeing something special here. He said SGEN is looking to accelerate that program by gaining permission to move from Phase 1 directly to a pivotal study.
- In quickly running through the long list of collaborations, he mentioned three companies specifically: Genentech, Abbvie and Genmab. Let the speculation begin.
- Importantly, a revenue slide added clarity to the financial projections that the company somewhat botched during the most recent conference call. It is now crystal clear that collaboration revenue DOES NOT include royalty revenue. For 2014, the slide breaks out Adcetris net sales at $178.2 million, collaboration revenue at $68.6 million and royalty revenue (all from Takeda) at $40 million. For 2015, the slide breaks out expected Adcetris sales of $200-210 million (a significant gain over last year), and collaboration revenue at $60-70 million (about the same as in 2014). There is no projection for royalty revenue, as that only can be predictive of another company's sales, and SGEN is not in the position to do that. Of royalty revenue, however, Siegall said: "We expect that to grow."
That's all I have.
As always, you are encouraged to listen to the replay.
Unlikely. They never break news at an investor conference. But if they do have news to release, it will come in the form of a press release issued at some point before the 8:30 a.m. EDT conference.
And, right on cue, there he is. Pipelight, another alias of the troll Ricarooski. Check out his previous posts elsewhere. Same muddy thinking, same typos, same counting of thumbs down. Ricky, Maiu Smelky, fsout, Pipelight and more. The man of a thousand aliases.
(You'll note that, upon being busted [again], Rickarooski/Maui deleted his most recent posts and fled the scene. Look for "fsout" or one of his many other aliases to show up shortly. This is one ill puppy.)
Keep in mind that Maui is one of the many aliases of the troll we know as Rickarooski. This is the alias he uses when he wants to seem reasonably bullish, but always with hesitation and doubt.
Felix Baker bought nearly 450,000 MORE shares in the last few days. If you think all of these huge recent buys by the Bakers are meaningless, you're nuts.
Siegall didn't do the presentation. It was Eric Dobmeier, the chief operating officer, and he said nothing negative or, frankly, interesting. No new information of any kind was presented. The drop could not - or should not - be related to the presentation. This is just market stuff. The company is the same company it was yesterday, last week, last month and last quarter.
Agreed. Follow the insiders, especially at SGEN. The Bakers are our canaries in the coal mine. Aside from that, the only time you make money in the market these days is when you accidentally get on the same side as the deep-pocketed manipulators.
Felix Baker is on the board of directors. By definition, that makes him an insider with inside information. That doesn't mean that he gets a peek at unreleased trial data, but it does mean that he is rather more likely to have insight into what the company has going for it and what the future is likely to bring than, say, a troll like rickracki/maui/fsout/smelky. So, when the Bakers buy - within a short period of tine - millions of shares to add to their already heavy holding, logic suggests that they know something that is encouraging.
Good news, for sure, but brace yourself. In the recent past, big buys by the Bakers have emboldened some shorts, because stock transactions by board members and other insiders imply that no buyout is on the table - the biggest risk facing a biotech short. This could mean another short-term setback in the pps, but long-term this is nothing but a positive leading indicator: No one is more successful as biotech investors than the Bakers, they essentially are in control of Seattle Genetics now, Felix Baker is SGEN's lead independent director (as inside as you can get), and - given their recent series of huge buys - they clearly have reason to expect an extremely bright future for SGEN - and for shareholders.